Biotechnology US biotech major Amgen has entered into a collaboration with Swiss pharma giant Roche on a Phase Ib study to evaluate the safety and efficacy of talimogene laherparepvec (T-Vec), Amgen's investigational oncolytic immunotherapy, in combination with Roche's investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases. 3 June 2015